欢迎访问上海芮晖化工科技有限公司官方网站！
咨询电话: 021-31433387|邮箱: sales@rechemscience.com
产品分类
联系我们
| 电话： | 021-31433387 |
| 15618786686 | |
| Email: | sales@rechemscience.com |
| info@rechemscience.com | |
| QQ: | 1369748377 |
| Skype: | rechem@outlook.com |
| 目录号 | 产品名称 | 产品描述 |
| R10302 | CO1686 Intermediate1 | Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibit |
| R10303 | CO1686 Intermediate2 | Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibit |
| R10304 | CO1686 Intermediate3 | Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibit |
| R10305 | HKI272; HKI272; Neratinib Intermediate1 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10306 | HKI272; HKI272; Neratinib Intermediate2 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10307 | HKI272; HKI272; Neratinib Intermediate3 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10308 | HKI272; HKI272; Neratinib Intermediate4 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10309 | E7080; E7080; Lenvatinib Intermediate1 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10310 | E7080; E7080; Lenvatinib Intermediate2 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10311 | E7080; E7080; Lenvatinib Intermediate3 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10312 | E7080; E7080; Lenvatinib Intermediate4 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10315 | PD0332991; Palbociclib Intermediate1 | Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 wi |
| R10316 | PD0332991; Palbociclib Intermediate2 | Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 wi |
| R10317 | PD0332991; Palbociclib Intermediate3 | Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 wi |
| R10318 | Valsartan/sacubitril; LCZ696 Intermediate1 | LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally |
| R10319 | Valsartan/sacubitril; LCZ696 Intermediate2 | LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally |
| R10320 | Valsartan/sacubitril; LCZ696 Intermediate3 | LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally |
| R10323 | ML190; Indomethacin morpholinylamide | |
| R10387 | Allantoin | |
| R10388 | Repaglinide | |
| R10389 | Metformin hydrochloride | |
| R10390 | Phenformin Hydrochloride | |
| R10391 | Pioglitazone Hydrochloride | |
| R10392 | Glibenclamide; Glyburide | |
| R10393 | Glimepiride |
